NeuroScientific Biopharmaceuticals is an Australian public company (ASX:NSB) that specializes in developing novel peptide-based pharmaceutical products targeting neurological disorders and eye diseases with high unmet medical needs. Their innovative approach aims to transform the understanding and treatment of neurodegenerative diseases like Alzheimer's. With a focus on neuroscience, NeuroScientific believes in the immense potential for medical breakthroughs in this field.

The company is supported by a board of experienced professionals in biopharmaceuticals, commercial medicine, and corporate leadership. NeuroScientific's executive team includes Dougal Thring, VP of Clinical Development, who oversees clinical strategy and regulatory operations. The company's CFO and Company Secretary, Abby Macnish Niven, is a chartered financial analyst with extensive investment experience.

Furthermore, NeuroScientific is proud to collaborate with esteemed institutions such as the Lions Eye Institute for ophthalmology studies and Covance for preclinical development solutions. With a strong heritage and partnerships, NeuroScientific Biopharmaceuticals is committed to advancing scientific research and delivering innovative medical solutions